Skip to Content
Merck
  • The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists.

The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists.

Bioorganic & medicinal chemistry letters (2012-03-17)
Jay M Matthews, Ning Qin, Raymond W Colburn, Scott L Dax, Mike Hawkins, James J McNally, Laura Reany, Mark A Youngman, Judith Baker, Tasha Hutchinson, Yi Liu, Mary Lou Lubin, Michael Neeper, Michael R Brandt, Dennis J Stone, Christopher M Flores
ABSTRACT

A series of benzothiophene-based phosphonates was synthesized and many analogs within the series were shown to be potent antagonists of the TRPM8 channel. The compounds were obtained as a racemic mixture in 5 synthetic steps, and were tested for TRPM8 antagonist activity in a recombinant, canine TRPM8-expressing cell line using a fluorometric imaging plate reader (FLIPR) assay. Structure-activity relationships were developed initially by modification of the core structure and subsequently by variation of the aromatic substituents and the phosphonate ester. Compound 9l was administered intraperitoneally to rats and demonstrated engagement of the TRPM8 target in both prevention and reversal-modes in an icilin-induced 'wet-dog' shake model.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3,4-Difluorobenzyl bromide, 98%